Sector
PharmaceuticalsOpen
₹996.9Prev. Close
₹977.35Turnover(Lac.)
₹0.28Day's High
₹996.9Day's Low
₹952.352 Week's High
₹1,30352 Week's Low
₹721.15Book Value
₹430.79Face Value
₹10Mkt Cap (₹ Cr.)
117.96P/E
29.4EPS
33.24Divi. Yield
0.36Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 1.2 | 1.2 | 1.2 | 1.2 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 49.64 | 44.43 | 39.11 | 35.69 |
Net Worth | 50.84 | 45.63 | 40.31 | 36.89 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 68.6 | 57.26 | 51.86 | 48.02 |
yoy growth (%) | 19.78 | 10.41 | 7.99 | 1.07 |
Raw materials | -31.16 | -25.64 | -23.83 | -20.22 |
As % of sales | 45.43 | 44.77 | 45.94 | 42.11 |
Employee costs | -9.79 | -9.3 | -7.33 | -6.9 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 7.9 | 4.32 | 2.45 | 4.89 |
Depreciation | -1.92 | -1.86 | -1.47 | -1.28 |
Tax paid | -2.57 | -1.1 | -0.44 | -2.19 |
Working capital | 2.51 | 0.57 | 1.74 | 3.08 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 19.78 | 10.41 | 7.99 | 1.07 |
Op profit growth | 55.54 | 40.92 | -34.9 | 3.8 |
EBIT growth | 66.14 | 53.04 | -41.88 | -4.64 |
Net profit growth | 65.34 | 60.34 | -25.51 | -31.08 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,804.8 | 157.5 | 4,34,195.65 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,130.1 | 88.09 | 1,61,829.65 | 518 | 0.49 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,477.6 | 28.59 | 1,21,053.04 | 1,178.16 | 0.87 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,332.25 | 69.57 | 1,13,812.4 | 460 | 0.83 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,585.1 | 52.35 | 1,04,937.42 | 634.43 | 0 | 2,529.74 | 269.23 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Rajendra R Shah
Non Executive Director
Dilip R Shah
Independent Non Exe. Director
Bharat Dhirajlal Mehta
Non-Exec & Non-Independent Dir
Paresh Mistry
Non Executive Director
Janki Shah
Independent Director
Jayantilal D Raval
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Mercury Laboratories Ltd
Summary
Mercury Laboratories Limited, the registered partnership firm started its business activity in year 1962. Subsequently, the Company converted into Private Limited Company & incorporated in February, 1982. Later, it further converted into Limited Company in 1992 in Maharashtra. The Company is engaged in the business of Pharmaceutical items, medicinal drugs and formulations. It is a profit making and dividend paying public limited company.
Read More
The Mercury Laboratories Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹983 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Mercury Laboratories Ltd is ₹117.96 Cr. as of 06 Dec ‘24
The PE and PB ratios of Mercury Laboratories Ltd is 29.4 and 2.27 as of 06 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Mercury Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Mercury Laboratories Ltd is ₹721.15 and ₹1303 as of 06 Dec ‘24
Mercury Laboratories Ltd's CAGR for 5 Years at 28.96%, 3 Years at 16.29%, 1 Year at 24.98%, 6 Month at 10.29%, 3 Month at -5.11% and 1 Month at 1.86%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice